Antifolate C2

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H561686

CAS#: 1286279-90-0

Description: Antifolate C2, also known as AGF154, is an inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC).

Chemical Structure

img
Antifolate C2
CAS# 1286279-90-0
Instruction

Theoretical Analysis

Hodoodo Cat#: H561686
Name: Antifolate C2
CAS#: 1286279-90-0
Chemical Formula: C19H21N5O6S
Exact Mass: 447.12
Molecular Weight: 447.460
Elemental Analysis: C, 51.00; H, 4.73; N, 15.65; O, 21.45; S, 7.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Antifolate C2; AGF154; AGF-154; AGF 154;

IUPAC/Chemical Name: (S)-2-({5-[3-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)-propyl]-thiophene-3-carbonyl}-amino)-pentanedioic acid

InChi Key: RMEHPWHLFJJYTB-ZDUSSCGKSA-N

InChi Code: InChI=1S/C19H21N5O6S/c20-19-23-15-12(17(28)24-19)7-10(21-15)2-1-3-11-6-9(8-31-11)16(27)22-13(18(29)30)4-5-14(25)26/h6-8,13H,1-5H2,(H,22,27)(H,25,26)(H,29,30)(H4,20,21,23,24,28)/t13-/m0/s1

SMILES Code: O=C(O)[C@@H](NC(C1=CSC(CCCC(N2)=CC3=C2N=C(N)NC3=O)=C1)=O)CCC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 447.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Wilson MR, Hou Z, Yang S, Polin L, Kushner J, White K, Huang J, Ratnam M, Gangjee A, Matherly LH. Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates. Mol Pharmacol. 2016 Apr;89(4):425-34. doi: 10.1124/mol.115.102798. Epub 2016 Feb 2. PubMed PMID: 26837243; PubMed Central PMCID: PMC4809305.

2: Laverdière I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socié G, Lévesque É. Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica. 2015 Feb;100(2):275-83. doi: 10.3324/haematol.2014.109884. Epub 2014 Nov 25. PubMed PMID: 25425682; PubMed Central PMCID: PMC4803136.

3: Ho C, Ramsden K, Zhai Y, Murray N, Sun S, Melosky B, Laskin J. Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review. J Thorac Oncol. 2014 Aug;9(8):1180-6. doi: 10.1097/JTO.0000000000000225. PubMed PMID: 25157771.

4: Majorczyk E, Pawlik A, Gendosz D, Kuśnierczyk P. Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment. BMC Musculoskelet Disord. 2014 Jul 28;15:256. doi: 10.1186/1471-2474-15-256. PubMed PMID: 25069714; PubMed Central PMCID: PMC4118653.

5: Chen S, Cai J, Zhang W, Zheng X, Hu S, Lu J, Xing J, Dong Y. Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58. doi: 10.3892/ijo.2014.2389. Epub 2014 Apr 16. PubMed PMID: 24736981.

6: Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LL, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis. 2013 Oct 24;4:e877. doi: 10.1038/cddis.2013.393. PubMed PMID: 24157871; PubMed Central PMCID: PMC3920946.

7: Gambra MP, Bidart T. [Prophylaxis against Pneumocystis pneumonia in pediatric and adult patients undergoing solid organ or hematopoietic stem cells transplantation]. Rev Chilena Infectol. 2012 Sep;29 Suppl 1:S19-22. doi: 10.4067/S0716-10182012000500003. Review. Spanish. PubMed PMID: 23282551.

8: Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov;136(1):169-78. doi: 10.1007/s10549-012-2256-5. Epub 2012 Sep 23. PubMed PMID: 23001754; PubMed Central PMCID: PMC5472381.

9: Desmoulin SK, Wang L, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol. 2012 Oct;82(4):591-600. Epub 2012 Jun 26. PubMed PMID: 22740639; PubMed Central PMCID: PMC3463226.

10: Novais A, Baquero F, Machado E, Cantón R, Peixe L, Coque TM. International spread and persistence of TEM-24 is caused by the confluence of highly penetrating enterobacteriaceae clones and an IncA/C2 plasmid containing Tn1696::Tn1 and IS5075-Tn21. Antimicrob Agents Chemother. 2010 Feb;54(2):825-34. doi: 10.1128/AAC.00959-09. Epub 2009 Dec 7. PubMed PMID: 19995930; PubMed Central PMCID: PMC2812134.

11: Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, Joseph A, Reddy V, Eisen S, McLeod HL. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):572-9. Epub 2008 Mar 15. PubMed PMID: 18381794.

12: Haug G, Wilde C, Leemhuis J, Meyer DK, Aktories K, Barth H. Cellular uptake of Clostridium botulinum C2 toxin: membrane translocation of a fusion toxin requires unfolding of its dihydrofolate reductase domain. Biochemistry. 2003 Dec 30;42(51):15284-91. PubMed PMID: 14690438.

13: Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44. Epub 2003 Apr 17. PubMed PMID: 12702717.

14: Antunes NL, Wolden S, Souweidane MM, Lis E, Rosenblum M, Steinherz PG. Radiation myelitis in a 5-year-old girl. J Child Neurol. 2002 Mar;17(3):217-9. PubMed PMID: 12026238.

15: Trimmer EE, Ballou DP, Ludwig ML, Matthews RG. Folate activation and catalysis in methylenetetrahydrofolate reductase from Escherichia coli: roles for aspartate 120 and glutamate 28. Biochemistry. 2001 May 29;40(21):6216-26. PubMed PMID: 11371182.

16: Cody V, Galitsky N, Luft JR, Pangborn W, Rosowsky A, Blakley RL. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523. Biochemistry. 1997 Nov 11;36(45):13897-903. PubMed PMID: 9374868.

17: Hennequin LF, Boyle FT, Wardleworth JM, Marsham PR, Kimbell R, Jackman AL. Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent. J Med Chem. 1996 Feb 2;39(3):695-704. PubMed PMID: 8576912.

18: Morgan WD, Birdsall B, Polshakov VI, Sali D, Kompis I, Feeney J. Solution structure of a brodimoprim analogue in its complex with Lactobacillus casei dihydrofolate reductase. Biochemistry. 1995 Sep 19;34(37):11690-702. PubMed PMID: 7547901.

19: Marsham PR, Jackman AL, Barker AJ, Boyle FT, Pegg SJ, Wardleworth JM, Kimbell R, O'Connor BM, Calvert AH, Hughes LR. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series. J Med Chem. 1995 Mar 17;38(6):994-1004. PubMed PMID: 7699716.

20: Boccaccio C, Meunier-Rotival M, Deschatrette J. Analysis of the inductive effect of the genomic equivalent of HALF1 sequence in the reversion of rat dedifferentiated hepatoma cells. Exp Cell Res. 1994 Jul;213(1):113-20. PubMed PMID: 8020580.